Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01475461 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes

A Phase 2 study, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
345
Enrollment target

NCT01475461 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 345 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01475461, a Phase 2 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
345 participants
Enrollment target

Study Summary

B1621007 is designed to study the safety and efficacy of PF-04937319 in patients with type 2 diabetes

Interventions

  • DRUG Placebo
  • DRUG PF-04937319 - 3mg
  • DRUG PF-04937319 - 20mg
  • DRUG PF-04937319 - 50mg
  • DRUG PF-04937319 - 100mg

Trial Details

FieldValue
Enrollment Target 345 participants
Start Date 2011-11
Est. Completion 2013-01
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT01475461

The ClinicalTrials.gov registry entry for NCT01475461 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.

NCT01475461 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01475461 about?

NCT01475461 is a clinical study titled "Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes". B1621007 is designed to study the safety and efficacy of PF-04937319 in patients with type 2 diabetes

What is the current status of trial NCT01475461?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 345 participants. The study started on 2011-11. Estimated completion is 2013-01.

What interventions are being tested in trial NCT01475461?

The interventions under investigation include: Placebo (DRUG), PF-04937319 - 3mg (DRUG), PF-04937319 - 20mg (DRUG), PF-04937319 - 50mg (DRUG), PF-04937319 - 100mg (DRUG).

Who is sponsoring clinical trial NCT01475461?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.